Emerging Therapies for Glioblastoma: A Glimpse of Hope Against a Relentless Cancer
· Gena Health Team
Glioblastoma (GBM) remains one of the most aggressive and incurable brain cancers, with survival rates extremely low despite decades of research. Standard treatment such as surgery, radiotherapy, and chemotherapy rarely extends survival beyond 15–18 months. However, several recent clinical trials and experimental therapies are sparking optimism. Here’s a summary of some of the most promising approaches currently under investigation.
1. Gilead’s Dual-Target CAR-T Cell Therapy
CAR-T therapies have transformed the landscape for certain blood cancers, and now researchers are exploring their potential in solid tumours like GBM. Gilead’s Kite cell therapy unit has developed a dual-target CAR-T therapy that engineers patients’ own T-cells to attack two tumoor markers: EGFR and IL-13Rα2.
How it works: The modified T-cells (immune cells) are infused into the spinal fluid, enabling them to circulate directly in the brain.
Trial results: In an early-phase trial with 18 patients, 62% with measurable tumors saw shrinkage, while others achieved disease stability for over a year. However, most relapsed after 2–3 months.
Next steps: Gilead plans to add a third target to prolong persistence in the brain and reduce relapse risk.
2. Patient-Derived Double-Loaded Dendritic Cell Therapy (DOC1021)
Immunotherapy strategies are also targeting GBM using dendritic cells, the body’s “master immune messengers.” Diakonos Oncology Corp. has developed Dubodencel (DOC1021), which combines tumor lysate with amplified tumor-derived mRNA to train the immune system to recognize and attack tumor cells.
Phase I results: The trial showed striking results, with a 12-month overall survival (OS) rate of 88%, compared to the typical ~60% with standard of care.
Next steps: The first patient has already been dosed in a Phase II trial, expanding the scope of testing.
3. TT Fields in the PORTRAIT Trial (The Christie NHS Foundation Trust)
Tumor Treating Fields (TT Fields) are already approved for recurrent GBM, but the PORTRAIT trial is breaking new ground by using them immediately after diagnosis, even before surgery and radiotherapy.
How it works: TT Fields use low-intensity electrical pulses to disrupt tumor cell division, slowing or halting tumor growth.
Why is it important: This is the first global study to test TT Fields before standard treatments, with the aim of improving outcomes right from diagnosis.
4. Checkpoint Inhibitor Ipilimumab at UCLH
Checkpoint inhibitors have revolutionized treatment for melanoma and lung cancers, but their role in brain tumors has been uncertain. A pioneering trial at UCLH (University College London Hospitals) is now testing Ipilimumab, a monoclonal antibody that blocks CTLA-4, unleashing the immune system against GBM.
Early testing: The first patient treated with Ipilimumab remains tumor-free on scans even after 2.5 years.
What’s new: Patients in this study receive the immunotherapy before any surgery or radiation, giving the immune system a chance to mount a defense early.
Next steps: The trial is expanding recruitment to more patients.
A New Era for GBM Treatment?
While GBM remains a devastating diagnosis, these innovative therapies represent meaningful progress. From engineered CAR-T cells to immune-priming dendritic vaccines, electrical field disruption, and checkpoint blockade, researchers are attacking the cancer from multiple angles.
The journey is far from over, but for patients and families facing GBM, these trials offer a much-needed glimmer of hope.
At Gena Health, we are constantly supporting the GBM patients to identify and access these innovative treatment options outside the standard of care. Have a chat with us to see how we help you navigate you cancer care.